SCHEDULE 13G/A: EcoR1 Capital Discloses 1.1% Passive Stake in Kalaris Therapeutics

EcoR1 Capital, LLC and affiliated entities have filed an amended Schedule 13G, reporting a 1.1% beneficial ownership stake in Kalaris Therapeutics, Inc. as of March 31, 2025.

Summary

• EcoR1 Capital, LLC, Oleg Nodelman, and EcoR1 Capital Fund Qualified, L.P. jointly reported beneficial ownership of Kalaris Therapeutics, Inc. common stock.
• As of March 31, 2025, EcoR1 Capital, LLC and Oleg Nodelman each beneficially owned 201,718 shares of Kalaris Therapeutics common stock, representing 1.1% of the outstanding class.
• EcoR1 Capital Fund Qualified, L.P. beneficially owned 191,242 shares, representing 1.0% of the outstanding common stock.
• The reported percentages are calculated based on 18,702,413 shares of Common Stock outstanding on March 18, 2025, as previously reported by Kalaris Therapeutics in a Form 8-K.
• The reporting persons, including EcoR1 Capital, LLC as an investment adviser and Oleg Nodelman as its control person, disclaim beneficial ownership of the securities except to the extent of their pecuniary interest.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing disclosing beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or outlook.

Future Outlook

NA

Industry Context

NA

Key Dates

Keywords

Kalaris Therapeutics, EcoR1 Capital, Oleg Nodelman, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Passive Investment